DOI: 10.1093/ced/llad272 ISSN:

An effective personal supporting intervention for topical treatment is also cost-effective for psoriasis

Mathias Tiedemann Svendsen, Klaus Ejner Andersen, Steven R Feldman, Anna Mejldal, Sören Möller, Line Planck Kongstad
  • Dermatology



Topical treatment combined with regular patient-support provided by dermatological nurses in structured consultations of 20-minuts duration every fourth weeks improved psoriasis severity, quality of life, and treatment adherence compared to topical treatment combined with standard patient-support which is seeing a dermatologist every third month.


To examine economic impact of the patient support from a healthcare sector perspective.


Costs for primary care, secondary healthcare services, and costs of prescription medication were compared for the intervention and non-intervention group over 48 weeks. Health benefits were expressed in terms of quality-adjusted life-years (QALYs) measured by the EuroQoL five-dimension three-level questionnaire. Regression analyses were used to estimate incremental cost and QALYs.


The incremental cost was estimated at £462, with an average increase of 0.08 QALYs per patients for patients receiving the intervention compared to patients receiving standard care. The incremental cost-effectiveness ratio for patients was £5,999/QALY. The intervention had an almost 100% probability of being cost-effective at a willingness-to-pay threshold of £30,000 per QALY.


Addressing adherence issues is critical to improving psoriasis patients’ topical treatment outcomes. The personal support intervention was effective with an acceptable increase in costs.

More from our Archive